Latest Capital Raises News

ADX Energy is progressing its HOCH-1 shallow gas well in Upper Austria, targeting up to 17.3 BCF of prospective gas resources with drilling at 950 metres depth and plans for two more wells this year.

Australian Mines Limited has raised $3 million through a strategic placement led by Tribeca Investment Partners to fast-track its Flemington Scandium Project from scoping to pre-feasibility study, aiming to de-risk and advance permitting.

Ballymore Resources is raising $3.24 million through a non-renounceable entitlement offer to fund drilling, geophysical surveys, and trial mining across key Queensland projects, including Dittmer and Ruddygore.

Botala Energy Ltd has denied holding undisclosed information following a sharp share price rise, linking the spike to a recent Serowe CBM Project announcement and confirming compliance with ASX disclosure rules.

Breakthrough Minerals (ASX:BTM) has secured A$5.15 million through a placement to fund a substantial expansion of its drilling program at the North Queensland Copper-Gold Project, aiming to grow its resource base beyond 200,000 tonnes of contained copper equivalent.

Avira Resources has cleared all major regulatory and heritage hurdles to kick off a 4,500-metre RC drilling campaign at its high-grade Mt Cattlin Gold Project, aiming for a maiden resource estimate by year-end.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

Condor Energy secures A$2.25 million in a placement to advance licence conversion, gas commercialisation, and exploration drilling readiness in its offshore Peru portfolio.

American West Metals (ASX: AW1) has raised A$10 million through an oversubscribed institutional placement to fast-track exploration at its West Desert and Storm Copper projects, focusing on high-demand critical metals.

Athena Resources is raising $3.5 million through a discounted share placement backed by major investors to fast-track drilling and feasibility at its Narryer magnetite project.

PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.